No Data
Buy Rating Affirmed for Leap Therapeutics on Strong Trial Prospects and Solid Financials
Leap Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Leap Therapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : Maintaining the Leap Therapeutics (LPTX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $7.00 to $5.50.
HC Wainwright & Co. : Maintaining the Leap Therapeutics (LPTX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $7.00 to $5.50.
HC Wainwright & Co. Maintains Buy on Leap Therapeutics, Lowers Price Target to $5.5
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Leap Therapeutics (NASDAQ:LPTX) with a Buy and lowers the price target from $7 to $5.5.
Leap Therapeutics Inc (LPTX) Q1 2024 Earnings: Financial Resilience Amidst Clinical Progress
Leap Therapeutics Says Net Proceeds From April 2024 $37.2M Financing, Combined With Existing Cash, Cash Equivalents And Marketable Securities Of $54.9M, Are Expected To Provide Cash Runway Into The Second Quarter Of 2026
Leap Therapeutics Says Net Proceeds From April 2024 $37.2M Financing, Combined With Existing Cash, Cash Equivalents And Marketable Securities Of $54.9M, Are Expected To Provide Cash Runway Into The Se